Skip to main content
Erschienen in: The Journal of Headache and Pain 1/2015

Open Access 01.12.2015 | Poster presentation

P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center

verfasst von: Ennio Pucci, Luca Diamanti, Silvano Cristina, Fabio Antonaci, Alfredo Costa

Erschienen in: The Journal of Headache and Pain | Sonderheft 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Background

Coenzyme Q-10 (ubiquinone) is a small hydrophobic substance that acts as an electron carrier in the mitochondrial respiratory chain. Its main activity is to protect DNA, proteins and lipids from oxidative stress. In the literature, a role of brain oxidative metabolism in the pathogenesis of migraine has been hypothesized [1]. Few clinical trials are described using coenzyme Q-10 in migraine prophylaxis, even in pediatrics [24]. The aim of this work was to present our experience of migraine prevention, prescribing coenzyme Q-10 to 20 adult patients with migraine without aura.

Materials and methods

Patients were enrolled in a tertiary headache center and followed for a period of 60 days (visit 1 and visit 2). The dose of coenzyme Q-10 was 200 mg/day. Visual analogue scale (VAS) was used to measure pain.

Results

In our cohort, male/female ratio was 1:5, while the mean age was 32.1 years (range, 22-49 years). Patients had a relatively short history of disease (mean 5.6 years; range 2-18), indeed only 2 of them were on a first-line treatment whereas coenzyme Q-10 was the starting therapy for others. We noticed a significant reduction of the number of crises at visit 2 (mean 3.15 vs 0.9, p < 0.05), as well as VAS score (mean 6.65 vs 1.45, p < 0.05) and monthly days of headache (mean 6.3 vs 1.5, p < 0.05). No one showed side effects, body weight did not vary (mean 56.55 vs mean 56.65) and patients did not even experience drastic weight loss or gain. The drug was well tolerated with a mean satisfaction score of 7.65 (range, 0-10). Moreover, patients reported positive effects on fatigue.

Conclusions

Coenzyme Q-10 is a safe and effective therapy for migraine prophylaxis.
Written informed consent to publish was obtained from the patient(s).

Conflict of interest

None. This study did not receive any industry funding.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Literatur
1.
Zurück zum Zitat Montagna P, Sacquegna T, Cortelli P, Lugaresi E: Migraine as a defect of brain oxidative metabolism: a hypothesis. J Neurol. 1989, 236 (2): 124-125.CrossRefPubMed Montagna P, Sacquegna T, Cortelli P, Lugaresi E: Migraine as a defect of brain oxidative metabolism: a hypothesis. J Neurol. 1989, 236 (2): 124-125.CrossRefPubMed
2.
Zurück zum Zitat Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al: A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011, 31 (8): 897-905.CrossRefPubMed Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al: A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011, 31 (8): 897-905.CrossRefPubMed
3.
Zurück zum Zitat Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al: Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005, 64 (4): 713-715.CrossRefPubMed Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al: Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005, 64 (4): 713-715.CrossRefPubMed
4.
Zurück zum Zitat Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD: Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002, 22 (2): 137-141.CrossRefPubMed Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD: Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002, 22 (2): 137-141.CrossRefPubMed
Metadaten
Titel
P032. Coenzyme Q-10 and migraine: a lovable relationship. The experience of a tertiary headache center
verfasst von
Ennio Pucci
Luca Diamanti
Silvano Cristina
Fabio Antonaci
Alfredo Costa
Publikationsdatum
01.12.2015
Verlag
Springer Milan
Erschienen in
The Journal of Headache and Pain / Ausgabe Sonderheft 1/2015
Print ISSN: 1129-2369
Elektronische ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-16-S1-A139

Weitere Artikel der Sonderheft 1/2015

The Journal of Headache and Pain 1/2015 Zur Ausgabe

Invited speaker presentation

Obesity, diet and nutraceuticals

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.